

Accelerating efforts towards elimination and attainment of malaria-free status



Marketing authorization application of tafenoquine paediatric submitted to Australian Therapeutic Goods Administration

Ganaplacide–lumefantrine (frontrunner new combination therapy) progressed to Part B of the Phase IIb trial, with an additional paediatric study (KALUMI) starting in 2021

Cipargamin new formulation for intravenous administration completed Phase I with Phase II expected to start in 2021

To date, **6,500 new data points** have been generated from transmission-blocking assays performed in collaboration with Imperial College London

2.7 million lives estimated to have been saved to date through MMV-supported medicines

536 million courses of SPAQ delivered since its launch in 2014 for **seasonal malaria**, protecting over **30 million** children in 2020. Six new combinations of licensed molecules have been evaluated and ranked as alternatives to SPAQ for SMC.

430 million paediatric treatment courses of **Coartem® Dispersible** (artemether–lumefantrine) distributed to over 50 countries since 2009, saving an estimated **926,000 lives**

1.73 million patients treated with **Pyramax®** (pyronaridine–artesunate); tablets approved in 29 countries and granules in 19 countries

New candidate selected for development: ELQ331

11 compounds in preclinical and clinical development including 10 with novel biological pathways compared with existing ACTs

Strengthening the enabling environment



European and Developing Countries Clinical Trials Partnership (EDCTP)-funded **PAMAfrica training** to strengthen research capacity at trial sites and research capability of next-generation African scientists

Harnessing innovation and expanding research



Safeguarded continued SMC campaigns, protecting 30 million children in 2020

Promoted healthcare awareness in rural communities adapting existing malaria educational initiatives, e.g. training community health volunteers on danger signs and protocols around COVID-19

Over 50 COVID Boxes shipped to enable standardization of testing results across various laboratories

Worked with partners on COVID-19 clinical studies, including the ReACT and ANTICOV studies

The WHO Global Technical Strategy for Malaria 2016–2030¹ provides a framework and key targets for all malaria-endemic countries working towards control and elimination. Reaching these targets will contribute to achieving Sustainable Development Goal 3 ‘Ensure healthy lives and promote well-being for all at all ages’² In 2020, MMV and key partners made important strides towards meeting these targets by:

Investigation of next-generation combinations for uncomplicated malaria through the Malaria Drug Development Catalyst

Two potent compounds against *P. vivax* liver stages identified through screening

Three new regulatory approvals for Krintafel/Kozenis (tafenoquine),³ including in Thailand, the first South East Asian country to grant marketing authorization approval

3.8 million doses of **artesunate rectal capsules** delivered to date with registration in 17 countries, saving an estimated 443,000 lives

209 million vials of injectable artesunate delivered since launch, estimated to have saved **1.36 million additional lives** compared to treatment with injectable quinine⁴

7.9 million Eurartesim® (dihydroartemisinin–piperaquine) treatments distributed since approval with registration in 24 countries

A new pregnancy registry has been established to monitor the impact of different antimalarials on mother and child, inform policymakers and strengthen healthcare systems

Over 100 Pandemic Response Boxes shipped in 2019–2020 to facilitate drug discovery in other disease areas

Two compounds active against *Plasmodium cynomolgi* liver stages identified through screening

Four new late leads approved in 2020

Working beyond our scope: Response to the COVID-19 pandemic



Implemented measures to support supply chains for chloroquine to treat malaria in *P. vivax*-endemic countries and mitigate stockouts

¹ WHO Global Technical Strategy for Malaria 2016–2030: https://www.who.int/docs/default-source/documents/global-technical-strategy-for-malaria-2016-2030.pdf?sfvrsn=c82afcc_0
² UN Sustainable Development Goals (SDGs): https://www.who.int/health-topics/sustainable-development-goals#tab=tab_1
³ Tafenoquine is marketed as *Kozenis* in Australia and *Krintafel* in the USA. Trademarks are owned by or licensed to the GSK group of companies.
⁴ Assuming that patients would have received injectable quinine in the absence of injectable artesunate.